GSK2606414
CAS No. 1337531-36-8
GSK2606414( GSK2606414 | GSK-2606414 | GSK PERK Inhibitor )
Catalog No. M11350 CAS No. 1337531-36-8
GSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 55 | In Stock |
|
| 5MG | 86 | In Stock |
|
| 10MG | 116 | In Stock |
|
| 50MG | 314 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK2606414
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM.
-
DescriptionGSK2606414 is an orally available, potent, and selective PERK inhibitor with IC50 of 0.4 nM, displaying at least 100-fold selectivity over the other EIF2AKs assayed.(In Vitro):GSK2606414 inhibits PERK activation in cells.(In Vivo):GSK2606414 (50 and 150 mg/kg, p.o.) inhibits the growth of a human tumor xenograft in mice.
-
In VitroGSK2606414 inhibits PERK activation in cells.
-
In VivoGSK2606414 (50 and 150 mg/kg, p.o.) inhibits the growth of a human tumor xenograft in mice.
-
SynonymsGSK2606414 | GSK-2606414 | GSK PERK Inhibitor
-
PathwayApoptosis
-
TargetPERK
-
RecptoreIF-2AK1 (HRI)| eIF-2AK2 (PKR)| eIF-2AK3 (PERK)
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number1337531-36-8
-
Formula Weight451.44
-
Molecular FormulaC24H20F3N5O
-
Purity>98% (HPLC)
-
SolubilityEthanol: 19 mg/mL (42.08 mM); DMSO: 90 mg/mL (199.36 mM)
-
SMILESFC(C1=CC(CC(N2CCC3=C2C=CC(C4=CN(C)C5=NC=NC(N)=C54)=C3)=O)=CC=C1)(F)F
-
Chemical Name1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)indolin-1-yl)-2-(3-(trifluoromethyl)phenyl)ethanone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Axten JM, et al. J Med Chem. 2012, 55(16), 7193-7207.
molnova catalog
related products
-
Epieriocalyxin A
Epieriocalyxin A can suppress Caco-2 colon cancer cell growth. It could be a potential drug for colon cancer therapy in the future.
-
4E1rcat
4E1RCat is a dual inhibitor of eIF4E:eIF4G and eIF4E:4E-BP1 interaction, and inhibits the binding of eIF4G to eIF4E with IC50 of 3.2 μM.
-
BTdCPU
BTdCPU is a potent heme-regulated eIF2α kinase (HRI) activator.?BTdCPU promotes eIF2α phosphorylation and induced apoptosis in resistant cell.
Cart
sales@molnova.com